marked.bio

Company

Beijing Biotech

4 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

4 of 4 trials shown

  1. Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

    Recruiting Phase 1/2 Beijing Biotech Started 2026Primary completion 2027-04 NCT07627711

    EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)fludarabinecyclophosphamide

    …sh biopsy): • Arm A eligibility: MSLN positive and/or MUC1 positive. • Arm B eligibility: CLDN18.2 positive and/or MUC1 positive. (Example threshold: IHC 2+ or 3+ staining in \>=50% of tum…

    Claudin 18.2 expressionPancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease

  2. Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

    Recruiting Phase 1/2 Beijing Biotech Started 2026Primary completion 2027-02 NCT07480928

    EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)fludarabinecyclophosphamide

    …sh biopsy): • Arm A eligibility: MSLN positive and/or MUC1 positive. • Arm B eligibility: CLDN18.2 positive and/or MUC1 positive. (Example threshold: IHC 2+ or 3+ staining in \>=50% of tum…

    Claudin 18.2 expressionPancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease

  3. Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

    Recruiting Phase 1/2 Beijing Biotech Started 2026Primary completion 2027-03 NCT07622940

    EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cellsfludarabinecyclophosphamide

    Evidence of at least one selected target: CLDN18.2-positive by validated IHC (example threshold: membranous staining in

    Claudin 18.2 expressionRecurrent or Metastatic Esophageal Adenocarcinoma, Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease

  4. Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer

    Recruiting Phase 1/2 Beijing Biotech Started 2026Primary completion 2027-03 NCT07551362

    EB-DT-CAR-NKfludarabinecyclophosphamide

    Central confirmation of CLDN18.2-positive disease by immunohistochemistry, defined for this draft as membranous CLDN18.2 e…

    Claudin 18.2 expressionAdvanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma